Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Effects of spirulina (Arthrospira) platensis supplementation on inflammation, physical and mental quality of life, and anthropometric measures in patients with relapsing-remitting multiple sclerosis (RRMS): a triple-blinded, randomized, placebo-controlled trial.

  • 2025-08-28
  • Nutrition journal 24(1)
    • Sheno Karimi
    • Vahid Shaygannejad
    • Adel Mohammadalipour
    • Awat Feizi
    • Sahar Hooshmand
    • Marzieh Kafeshani

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 80
Population
80 RRMS patients (EDSS 0-6)
Methods
triple-blind, placebo-controlled trial randomized 80 RRMS patients to receive 1 g/day spirulina or placebo for 12 weeks
Blinding
Triple-blind
Duration
12 weeks
Funding
Unclear

Background

Multiple sclerosis (MS) is a chronic neuroinflammatory disorder marked by demyelination and axonal damage, where oxidative stress and cytokine-mediated inflammation are key pathological factors. Spirulina, a microalga rich in phycocyanin, phenolic compounds, and omega-3 fatty acids, exhibits potent antioxidant and anti-inflammatory properties, potentially targeting these pathways. This study investigated spirulina's impact on inflammatory biomarkers and quality of life in relapsing-remitting MS (RRMS) patients.

Methods

A triple-blind, placebo-controlled trial randomized 80 RRMS patients (EDSS 0-6) to receive 1 g/day spirulina (n = 40) or placebo (n = 40) for 12 weeks. Sixteen participants (20%) withdrew. Primary analysis followed the intention-to-treat (ITT) principle (N = 80) using baseline-observation-carried-forward for missing data. Serum IL-1β and IL-6 (primary outcomes) were measured by ELISA. Quality of life (MSQoL-54) and anthropometric measures were secondary outcomes.

Results

A linear mixed-effects model revealed that spirulina supplementation significantly reduced serum IL-1β (Estimate = - 1.07 ± 0.14, p < 0.001) and IL-6 levels (Estimate = - 2.66 ± 0.26, p < 0.001) compared to placebo. Significant improvements were also observed in health perception (Estimate = - 0.49 ± 0.12, p < 0.001), physical function (-0.37 ± 0.11, p < 0.001), role limitation-physical (-0.36 ± 0.16, p = 0.030), energy (-0.64 ± 0.15, p < 0.001), and sexual function (-1.31 ± 0.29, p < 0.001). No significant effects were found for emotional wellbeing, health distress, social function, cognitive function, sexual satisfaction, overall quality of life, or total mental health. Anthropometric analysis showed a significant weight reduction in the spirulina group versus placebo (-2.85 ± 1.13 kg, p = 0.015), while BMI reduction was borderline significant (-0.78 ± 0.41, p = 0.060). No significant changes were observed in waist circumference, waist-to-hip ratio, energy intake, or physical activity.

Conclusion

Spirulina supplementation significantly reduced pro-inflammatory markers and improved multiple physical and cognitive quality of life domains in patients with RRMS. Spirulina shows promise as a safe adjunct therapy in MS management, but larger trials with longer follow-up are warranted to confirm these findings and explore its clinical utility alongside DMTs.

Trial registration

The trial is registered with the Iranian Registry of Clinical Trials (ID IRCT2024124060794N1), with registration completed on 4 February 2024. Informed consent will be secured from each participant or their legal guardian.

Research Insights

Adverse Events Reported

  • Seaweed→Overall tolerability

    Spirulina shows promise as a safe adjunct therapy in MS management

    Finding
    Reported
Back to top